Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2019 from OUS - Radiation Biology and DNA Damage Signaling group
3 publications found
p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775
Cell Cycle, 18 (8), 834-847
Regulation of ATR activity via the RNA polymerase II associated factors CDC73 and PNUTS-PP1
Nucleic Acids Res, 47 (4), 1797-1813
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
Front Oncol, 9, 1301